TG Therapeutics, Inc.

NASDAQ:TGTX

Biotechnology

Healthcare
$66.12 +2.00%

+$1.03 today

Market cap
$9.99B
Beta
1.68
P/E (TTM)
16.4
EPS (TTM)
$3.20
52W Low $25.28High $53.98

Volume 1.87M

Average 2.15M

TGTX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

TG Therapeutics, Inc.NASDAQ: TGTX

Gross Margin · Q3 FY2026 · quarter ended Sep 2026

Gross margin widens to 83.8%

Gross margin was 83.8% in Q3 FY2026, up 1.2 pp from a year earlier. On a trailing-twelve-month basis it was 82.7%, down 2.6 pp year over year. Over 3 fiscal years it narrowed by 6.8 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
83.8%+1.0 pp QoQ
Last fiscal yearDec 2025
83.7%-4.6 pp YoY
LTMSep 2026
82.7%-2.6 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.2 pp——
1 year-4.6 pp——
3 years-6.8 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
83.7%
Year-over-year change
-4.6pp

Gross Margin vs competitors

How TGTX compares with its peers on the latest reported figures

  • TGTX's LTM Sep 2026 gross margin of 82.7% is the 4th highest of the 8 companies compared; the peer median is 69.9%.
  • Its year-over-year change of -2.6 pp is the 5th highest of 6, against a peer median of +0.0 pp.
  • Over three fiscal years its change of -6.8 pp compares with a peer median of +0.0 pp.
TGTX Competitors Peer median
Gross Margin for TGTX and competitors
Company Period LTM level YoY 3-year change
IPHAInnate Pharma S.A.FY2025100.0% +0.0 pp+89.6 pp
GMABGenmab A/SLTM Jun 202693.0% —-8.3 pp
ADCTADC Therapeutics S.A.LTM Mar 202690.7% -2.0 pp-7.9 pp
TGTXTG Therapeutics, Inc.LTM Sep 202682.7% -2.6 pp-6.8 pp
MGNXMacroGenics, Inc.LTM Mar 202669.9% +7.9 pp-24.0 pp
XNCRXencor, Inc.LTM Jun 202643.3% -18.0 pp+112.9 pp
ADAGAdagene Inc.LTM Jun 2024-14.6% —+0.0 pp
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-662.5% +5797.5 pp+3489.9 pp
CRVSCorvus Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding TGTX) 69.9%+0.0 pp+0.0 pp

Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.69M2.79M233.66M329M616.29M
Cost of Revenue790K265K14.13M38.49M100.71M
Gross Profit5.9M2.52M219.53M290.52M515.57M
Gross Margin88.2%90.5%94.0%88.3%83.7%
Research & Development222.58M125.35M76.19M94.29M160.22M
Selling, General & Admin128.09M95.48M122.71M154.3M232.03M
Operating Expenses350.67M220.84M198.9M248.59M392.25M
Depreciation & Amortization494K515K423K280K244K
EBITDA(341.97M)(213.11M)26.1M49.9M134.36M
EBITDA Margin-5112.4%-7651.9%11.2%15.2%21.8%
Operating Income(344.77M)(218.32M)20.63M41.93M123.32M
Operating Margin-5154.3%-7839.0%8.8%12.7%20.0%
Interest Income00000
Interest Expense5.64M10.19M12.62M24.03M26.73M
Other Income / Expenses(3.33M)(5.5M)(7.57M)(16.34M)(15.93M)
Income Before Tax(348.1M)(223.81M)13.06M25.59M107.39M
Pre-Tax Margin-5204.1%-8036.3%5.6%7.8%17.4%
Income Tax Expense00390K2.21M(339.79M)
Net Income(348.1M)(223.81M)12.67M23.38M447.18M
Net Margin-5204.1%-8036.3%5.4%7.1%72.6%
EPS (Basic)(2.63)(1.46)0.090.163.10
EPS (Diluted)(2.63)(1.46)0.090.152.77
Weighted Avg Shares132.22M135.41M141.96M145.32M144.32M
Weighted Avg Shares (Diluted)132.22M135.41M148.51M160.34M161.41M

TG Therapeutics, Inc.

NASDAQ:TGTX

Intrinsic Alpha fair value

Locked

Current Price

$66.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.